Doxycycline vs. macrolides in combination therapy for treatment of community-acquired pneumonia

Clin Microbiol Infect. 2012 Apr;18(4):E71-3. doi: 10.1111/j.1469-0691.2011.03759.x. Epub 2012 Jan 27.

Abstract

We assessed the comparative efficacy of empirical therapy with beta-lactam plus macrolide vs. beta-lactam plus doxycycline for the treatment of community-acquired pneumonia (CAP) among patients in the Australian Community-Acquired Pneumonia Study. Both regimens demonstrated similar outcomes against CAP due to either 'atypical' (Chlamydophila, Legionella or Mycoplasma spp.) or typical bacterial pathogens.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / therapeutic use
  • Australia / epidemiology
  • Chlamydophila / pathogenicity
  • Community-Acquired Infections / drug therapy*
  • Community-Acquired Infections / epidemiology
  • Community-Acquired Infections / microbiology
  • Doxycycline / therapeutic use*
  • Drug Therapy, Combination
  • Female
  • Gram-Negative Bacterial Infections / drug therapy
  • Gram-Negative Bacterial Infections / epidemiology
  • Gram-Negative Bacterial Infections / microbiology
  • Humans
  • Legionella / pathogenicity
  • Macrolides / therapeutic use*
  • Male
  • Middle Aged
  • Mycoplasma / pathogenicity
  • Mycoplasma Infections / drug therapy
  • Mycoplasma Infections / epidemiology
  • Mycoplasma Infections / microbiology
  • Pneumonia, Bacterial / drug therapy*
  • Pneumonia, Bacterial / epidemiology
  • Pneumonia, Bacterial / microbiology
  • Prospective Studies
  • Severity of Illness Index
  • Treatment Outcome
  • Young Adult
  • beta-Lactams / therapeutic use*

Substances

  • Anti-Bacterial Agents
  • Macrolides
  • beta-Lactams
  • Doxycycline